Quest Diagnostics Inc vs Super Micro Computer Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Super Micro Computer Inc trades at $41.85 (market cap $28.10B). The key difference: Quest Diagnostics Inc and Super Micro Computer Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Super Micro Computer Inc for 19 Days on average.
| DGX | SMCI | |
|---|---|---|
Market Cap | $25.48B | $28.10B |
Volume | 941,866 | 38,581,805 |
Sector | Health | Technology |
52-Week High | $247.45 | $57.98 |
52-Week Low | $173.49 | $20.53 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $31.23B | $33.56B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Super Micro Computer (SMCI) trades at $41.34, down 8.03% in the last session, but maintains strong fundamental performance with consistent earnings beats and robust revenue growth projections. The stock shows bullish technical signals with support at $40 and resistance at $44, while valuation metrics remain attractive with a P/E of 13.12 and P/S of 0.76. Recent news highlights AI server demand growth and new NVIDIA Vera Rubin platform shipments.
SMCI presents a compelling value opportunity with strong AI-driven growth prospects, though investors face risks from competitive pressures and potential regulatory scrutiny. Analyst consensus leans neutral with a $42.33 price target, while institutional interest remains strong given the company's positioning in the expanding AI infrastructure market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →